Lanadelumab improves health-related quality of life in patients with hereditary Angioedema (HAE): findings from the HELP study

被引：0
|
作者：
Longhurst, Hilary [1 ]
Lumry, William [2 ]
Weller, Karsten [3 ]
Magerl, Markus [3 ]
Lu, Peng [4 ]
Jain, Gagan [4 ]
Lewis, Hannah [5 ]
Maurer, Marcus [3 ]
机构：
[1] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Cambridge, England
[2] Allergy & Asthma Res Associates Res Ctr, Dallas, TX USA
[3] Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany
[4] Shire, Lexington, MA USA
[5] ICON Plc, London, England
来源：
CLINICAL AND EXPERIMENTAL ALLERGY | 2018年 / 48卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
OP.019
引用
收藏
页码：1524 / 1525
页数：2
相关论文
共 50 条
  • [21] Health-related quality of life among children with hereditary angioedema
    Engel-Yeger, Batya
    Farkas, Henriette
    Kivity, Shmuel
    Veszeli, Nora
    Kohalmi, Kinga Viktoria
    Kessel, Aharon
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2017, 28 (04) : 370 - 376
  • [22] C1-INH Therapy Improves Health-Related Quality of Life Measures in Patients with Hereditary Angioedema
    Bewtra, A.
    Jacobson, K. W.
    Craig, T.
    Packer, F.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S103 - S103
  • [23] Health related quality of life in hereditary angioedema patients
    Kuman, O.
    Demir, E.
    Gulbahar, O.
    Pirildar, S.
    Gokmen, Mete N.
    ALLERGY, 2017, 72 : 585 - 585
  • [24] BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): Findings from the APeX-1 study
    Magerl, M.
    Rae, W.
    Aygoeren-Puersuen, E.
    Bygum, A.
    Panovska, V. G.
    Steiner, U. C.
    Huissoon, A.
    Longhurst, H.
    Cicardi, M.
    Zanichelli, A.
    Triggiani, M.
    Fain, O.
    Lleonart, R.
    Katelaris, C.
    Aberer, W.
    Kinaciyan, T.
    Fang, L.
    Murray, S.
    Clemons, D.
    Joseph, K.
    Sheridan, W.
    Dobo, S.
    Collis, P.
    Cornpropst, M.
    Weller, K.
    Maurer, M.
    ALLERGY, 2018, 73 : 724 - 724
  • [25] Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention
    Martinez-Saguer, I
    Soteres, D.
    Van Leerberghe, A.
    Herrera, E. M.
    Devercelli, G.
    Vardi, M.
    Christensen, J.
    ALLERGY, 2018, 73 : 718 - 718
  • [26] Consistent Lanadelumab Treatment Effect In Patients With Hereditary Angioedema (HAE) Regardless Of Baseline Attack Frequency In The Phase 3 HELP Study
    Riedl, Marc A.
    Tachdjian, Raffi
    Schranz, Jennifer
    Nurse, Christina
    Bernstein, Jonathan A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB47 - AB47
  • [27] Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP Study
    Maurer, M.
    Gierer, S.
    Hebert, J.
    Hao, J.
    Lu, P.
    Bruelle, J.
    Banerji, A.
    SWISS MEDICAL WEEKLY, 2018, 148 : 36S - 36S
  • [28] Efficacy of lanadelumab in patients with HAE is independent of body mass index: Findings from the HELP study
    Zanichelli, A.
    Hebert, J.
    Soteres, D.
    Hao, J.
    Lu, P.
    Busse, P.
    ALLERGY, 2018, 73 : 722 - 723
  • [29] Health-related quality of life and its risk factors in Chinese hereditary angioedema patients
    Liu, Shuang
    Wang, Xue
    Xu, Yingyang
    Xu, Qun
    Zhi, Yuxiang
    ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (01)
  • [30] Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): Results of the phase 3 HELP study
    Maurer, M.
    Gierer, S.
    Hebert, J.
    Hao, J.
    Lu, P.
    Banerji, A.
    ALLERGY, 2018, 73 : 289 - 289
12345